232 related articles for article (PubMed ID: 29464314)
21. Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelve-month randomized, double-blind, placebo-controlled trial.
Quinn MA; Conaghan PG; O'Connor PJ; Karim Z; Greenstein A; Brown A; Brown C; Fraser A; Jarret S; Emery P
Arthritis Rheum; 2005 Jan; 52(1):27-35. PubMed ID: 15641102
[TBL] [Abstract][Full Text] [Related]
22. IgG and IgM anticardiolipin antibodies following treatment with infliximab plus methotrexate in patients with early rheumatoid arthritis.
Visvanathan S; Wagner C; Smolen J; St Clair EW; Hegedus R; Baker D; Keenan G
Arthritis Rheum; 2006 Sep; 54(9):2840-4. PubMed ID: 16948115
[TBL] [Abstract][Full Text] [Related]
23. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial.
St Clair EW; van der Heijde DM; Smolen JS; Maini RN; Bathon JM; Emery P; Keystone E; Schiff M; Kalden JR; Wang B; Dewoody K; Weiss R; Baker D;
Arthritis Rheum; 2004 Nov; 50(11):3432-43. PubMed ID: 15529377
[TBL] [Abstract][Full Text] [Related]
24. Neutrophils of rheumatoid arthritis patients on anti-TNF-α therapy and in disease remission present reduced adhesive functions in association with decreased circulating neutrophil-attractant chemokine levels.
Dominical VM; Bértolo MB; Almeida CB; Garrido VT; Miguel LI; Costa FF; Conran N
Scand J Immunol; 2011 Apr; 73(4):309-18. PubMed ID: 21208248
[TBL] [Abstract][Full Text] [Related]
25. Methotrexate dosage reduction in patients with rheumatoid arthritis beginning therapy with infliximab: the Infliximab Rheumatoid Arthritis Methotrexate Tapering (iRAMT) trial.
Fleischmann RM; Cohen SB; Moreland LW; Schiff M; Mease PJ; Smith DB; Keenan G; Kremer JM;
Curr Med Res Opin; 2005 Aug; 21(8):1181-90. PubMed ID: 16083527
[TBL] [Abstract][Full Text] [Related]
26. Serum proteomic analysis identifies interleukin 16 as a biomarker for clinical response during early treatment of rheumatoid arthritis.
Murota A; Suzuki K; Kassai Y; Miyazaki T; Morita R; Kondo Y; Takeshita M; Niki Y; Yoshimura A; Takeuchi T
Cytokine; 2016 Feb; 78():87-93. PubMed ID: 26700586
[TBL] [Abstract][Full Text] [Related]
27. Predictors of infusion reactions during infliximab treatment in patients with arthritis.
Kapetanovic MC; Larsson L; Truedsson L; Sturfelt G; Saxne T; Geborek P
Arthritis Res Ther; 2006; 8(4):R131. PubMed ID: 16869978
[TBL] [Abstract][Full Text] [Related]
28. Evolution of antinuclear antibodies and clinical patterns in patients with active rheumatoid arthritis with longterm infliximab therapy.
Comby E; Tanaff P; Mariotte D; Costentin-Pignol V; Marcelli C; Ballet JJ
J Rheumatol; 2006 Jan; 33(1):24-30. PubMed ID: 16395746
[TBL] [Abstract][Full Text] [Related]
29. Combination therapy of the chimeric monoclonal anti-tumor necrosis factor alpha antibody (infliximab) with methotrexate in patients with rheumatoid arthritis.
Antoni C; Kalden JR
Clin Exp Rheumatol; 1999; 17(6 Suppl 18):S73-7. PubMed ID: 10589362
[TBL] [Abstract][Full Text] [Related]
30. Six-transmembrane epithelial antigen of prostate 4 (STEAP4) is expressed on monocytes/neutrophils, and is regulated by TNF antagonist in patients with rheumatoid arthritis.
Tanaka Y; Matsumoto I; Iwanami K; Inoue A; Umeda N; Tanaka Y; Sugihara M; Hayashi T; Ito S; Sumida T
Clin Exp Rheumatol; 2012; 30(1):99-102. PubMed ID: 22244520
[TBL] [Abstract][Full Text] [Related]
31. Methotrexate Reduced TNF Bioactivity in Rheumatoid Arthritis Patients Treated with Infliximab.
Dénarié D; Rinaudo-Gaujous M; Thomas T; Paul S; Marotte H
Mediators Inflamm; 2017; 2017():3708250. PubMed ID: 28352145
[No Abstract] [Full Text] [Related]
32. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group.
Lipsky PE; van der Heijde DM; St Clair EW; Furst DE; Breedveld FC; Kalden JR; Smolen JS; Weisman M; Emery P; Feldmann M; Harriman GR; Maini RN;
N Engl J Med; 2000 Nov; 343(22):1594-602. PubMed ID: 11096166
[TBL] [Abstract][Full Text] [Related]
33. Calprotectin (S100A8/A9) and S100A12 are associated with measures of disease activity in a longitudinal study of patients with rheumatoid arthritis treated with infliximab.
Nordal HH; Brun JG; Hordvik M; Eidsheim M; Jonsson R; Halse AK
Scand J Rheumatol; 2016 Jul; 45(4):274-81. PubMed ID: 26767827
[TBL] [Abstract][Full Text] [Related]
34. Good response to infliximab in rheumatoid arthritis following failure of interleukin-1 receptor antagonist.
Bao J; Yue T; Li T; He DY; Bao YX
Int J Rheum Dis; 2016 Apr; 19(4):370-6. PubMed ID: 24798350
[TBL] [Abstract][Full Text] [Related]
35. Early and late effect of infliximab on circulating dendritic cells phenotype in rheumatoid arthritis patients.
Balanescu A; Radu E; Nat R; Regalia T; Bojinca V; Ionescu R; Balanescu S; Savu C; Predeteanu D
Int J Clin Pharmacol Res; 2005; 25(1):9-18. PubMed ID: 15864873
[TBL] [Abstract][Full Text] [Related]
36. FcgammaRIIa is a target for modulation by TNFalpha in human neutrophils.
Belostocki K; Park MS; Redecha PB; Masuda E; Salmon JE; Pricop L
Clin Immunol; 2005 Oct; 117(1):78-86. PubMed ID: 16084773
[TBL] [Abstract][Full Text] [Related]
37. Anti-Fc gamma receptor III autoantibody is associated with soluble receptor in rheumatoid arthritis serum and synovial fluid.
Lamour A; Baron D; Soubrane C; Cartron J; Khayat D; Adler Y; Le Goff P; Youinou P
J Autoimmun; 1995 Apr; 8(2):249-65. PubMed ID: 7612151
[TBL] [Abstract][Full Text] [Related]
38. Evaluation of the pharmacokinetic equivalence and 54-week efficacy and safety of CT-P13 and innovator infliximab in Japanese patients with rheumatoid arthritis.
Takeuchi T; Yamanaka H; Tanaka Y; Sakurai T; Saito K; Ohtsubo H; Lee SJ; Nambu Y
Mod Rheumatol; 2015; 25(6):817-24. PubMed ID: 25736355
[TBL] [Abstract][Full Text] [Related]
39. Anti-nuclear antibodies, anti-DNA and C4 complement evolution in rheumatoid arthritis and ankylosing spondylitis treated with TNF-alpha blockers.
Gonnet-Gracia C; Barnetche T; Richez C; Blanco P; Dehais J; Schaeverbeke T
Clin Exp Rheumatol; 2008; 26(3):401-7. PubMed ID: 18578960
[TBL] [Abstract][Full Text] [Related]
40. Serum levels of lipoprotein(a) and E-selectin are reduced in rheumatoid arthritis patients treated with methotrexate or methotrexate in combination with TNF-α-inhibitor.
Hjeltnes G; Hollan I; Førre O; Wiik A; Lyberg T; Mikkelsen K; Agewall S
Clin Exp Rheumatol; 2013; 31(3):415-21. PubMed ID: 23465067
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
